Home / PDSB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does PDSB make money? Does PDSB have pricing power? What's the Earnings Whisper? Will PDSB profit more as the business scales? What is PDSB's management track record? Is PDSB's current price justified?

PDS Biotechnology Corporation

$0.3 -$0.54 (-64.53%)

NASDAQ · 14 Sep 2026 16:27 UTC

Previous Close

$0.29

Day Range

$0.27$0.3

Year Range

$0.2$1.55

Market Cap

16.52M

AVG Volume

6.87M

Trailing/Forward PE

-0.48/-

PEG ratio

0.01

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Net Income (USD) · TTM

PDSB Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-33.67M
26 Q1	-33.36M
25 Q4	-34.5M
25 Q3	-34.88M
25 Q2	-36.6M
25 Q1	-35.5M
24 Q4	-37.61M
24 Q3	-40.56M
24 Q2	-40.68M
24 Q1	-43.89M

Operating Income (USD) · TTM

PDSB Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-27.83M
26 Q1	-28.96M
25 Q4	-31.54M
25 Q3	-32.23M
25 Q2	-34.27M
25 Q1	-35.33M
24 Q4	-36.32M
24 Q3	-39.37M
24 Q2	-39.71M
24 Q1	-43.72M

EBITDA (USD) · TTM

PDSB EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-27.13M
26 Q1	-27.92M
25 Q4	-30.3M
25 Q3	-30.7M
25 Q2	-32.35M
25 Q1	-33.07M
24 Q4	-33.78M
24 Q3	-36.64M
24 Q2	-36.91M
24 Q1	-40.85M

Cash Flows (USD) · TTM

PDSB Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-16.78M
26 Q1	-23.09M
25 Q4	-27.75M
25 Q3	-32.28M
25 Q2	-34.37M
25 Q1	-34.15M
24 Q4	-35.06M
24 Q3	-35.28M
24 Q2	-34.46M
24 Q1	-30.39M

EPS (USD) · TTM

PDSB EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-0.64
26 Q1	-0.67
25 Q4	-0.75
25 Q3	-0.83
25 Q2	-0.93
25 Q1	-0.95
24 Q4	-1.04
24 Q3	-1.16
24 Q2	-1.22
24 Q1	-1.36

Expenses (USD) · TTM

PDSB Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	3.09B
26 Q1	3.09B
25 Q4	31.54M
25 Q3	32.21M
25 Q2	34.25M
25 Q1	35.34M
24 Q4	36.34M
24 Q3	39.4M
24 Q2	39.74M
24 Q1	43.72M

Shares Outstanding · TTM

PDSB Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
26 Q2	-2.4M
26 Q1	-2.4M
25 Q4	-3.66M
25 Q3	-4.14M
25 Q2	-4.68M
25 Q1	-6.47M
24 Q4	-6.85M
24 Q3	-6.56M
24 Q2	-6.85M
24 Q1	-7.16M

Employee Count

PDSB Employee Count by quarter
Period	Employee Count
2025	21
2024	24
2023	25
2022	26
2021	22
2020	15
2019	15
2018	10
2017	38
2016	31

Free Cash Flow Yield

PDSB Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-102.25%
Sep 26	-137.06%
Aug 26	-142.97%
Aug 26	-138%
Aug 26	-130.76%
Aug 26	-53.67%
Jul 26	-60.65%
Jul 26	-61.06%
Jul 26	-56.62%
Jul 26	-53.77%
Jul 26	-48.77%
Jun 26	-46.83%
Jun 26	-43.57%
Jun 26	-39.63%
Jun 26	-40.79%
May 26	-38.53%
May 26	-34.67%
May 26	-31.05%
May 26	-47.86%
May 26	-61.01%
Apr 26	-66.44%
Apr 26	-45.67%
Apr 26	-55.4%
Apr 26	-94.22%
Mar 26	-127.23%
Mar 26	-120.63%
Mar 26	-109.16%
Mar 26	-102.36%
Feb 26	-102.04%
Feb 26	-106.3%
Feb 26	-98.29%
Feb 26	-96.34%
Jan 26	-82.71%
Jan 26	-72.51%
Jan 26	-72.41%
Jan 26	-64.37%
Jan 26	-82.67%
Dec 25	-76.18%
Dec 25	-77.38%
Dec 25	-70.71%
Dec 25	-79.17%
Nov 25	-89.34%
Nov 25	-91.18%
Nov 25	-81.95%
Nov 25	-82.22%
Oct 25	-80.07%
Oct 25	-81.42%
Oct 25	-80.83%
Oct 25	-79.04%
Oct 25	-73.4%
Sep 25	-73.4%
Sep 25	-71.31%
Sep 25	-64.54%
Sep 25	-62.39%
Aug 25	-60.38%
Aug 25	-62.92%
Aug 25	-62.92%
Aug 25	-75.93%
Aug 25	-77.33%
Jul 25	-71.43%
Jul 25	-73.29%
Jul 25	-67.97%
Jul 25	-63.37%
Jun 25	-59.78%
Jun 25	-52.03%
Jun 25	-48.16%
Jun 25	-49.87%
May 25	-61.08%
May 25	-53.35%
May 25	-59.36%
May 25	-80.15%
May 25	-69.69%
Apr 25	-76.94%
Apr 25	-89.05%
Apr 25	-93.38%
Apr 25	-101.23%
Mar 25	-76.33%
Mar 25	-69.97%
Mar 25	-77.93%
Mar 25	-77.93%
Feb 25	-72.07%
Feb 25	-71.53%
Feb 25	-61.45%
Feb 25	-65.66%
Jan 25	-58.45%
Jan 25	-61.84%
Jan 25	-66.11%
Jan 25	-67.98%
Jan 25	-53.25%
Dec 24	-56.06%
Dec 24	-58.09%
Dec 24	-52.1%
Dec 24	-44.17%
Nov 24	-43.77%
Nov 24	-45.86%
Nov 24	-47.69%
Nov 24	-28.54%
Nov 24	-29.35%
Oct 24	-30.1%
Oct 24	-28.89%

Price to Book

PDSB Price to Book by quarter
Period	Price to Book
Aug 26	11.05
Jul 26	9.78
Jul 26	9.71
Jul 26	10.48
Jul 26	11.03
Jul 26	12.16
Jun 26	12.67
Jun 26	13.62
Jun 26	14.97
Jun 26	14.54
May 26	15.4
May 26	17.11
May 26	19.1
May 26	6.27
May 26	4.92
Apr 26	4.51
Apr 26	6.57
Apr 26	5.41
Apr 26	3.18
Mar 26	2.68
Mar 26	2.83
Mar 26	3.13
Mar 26	3.34
Feb 26	3.35
Feb 26	3.21
Feb 26	3.47
Feb 26	3.54
Jan 26	4.13
Jan 26	4.71
Jan 26	4.72
Jan 26	5.3
Jan 26	4.13
Dec 25	4.48
Dec 25	4.41
Dec 25	4.83
Dec 25	4.31
Nov 25	3.82
Nov 25	3.75
Nov 25	4.17
Nov 25	2.62
Oct 25	2.69
Oct 25	2.64
Oct 25	2.66
Oct 25	2.72
Oct 25	2.93
Sep 25	2.93
Sep 25	3.02
Sep 25	3.34
Sep 25	3.45
Aug 25	3.57
Aug 25	3.42
Aug 25	3.42
Aug 25	2.01
Aug 25	1.98
Jul 25	2.14
Jul 25	2.08
Jul 25	2.25
Jul 25	2.41
Jun 25	2.55
Jun 25	2.94
Jun 25	3.17
Jun 25	3.06
May 25	2.5
May 25	2.86
May 25	2.57
May 25	2.3
May 25	2.65
Apr 25	2.4
Apr 25	2.07
Apr 25	1.98
Apr 25	1.82
Mar 25	2.42
Mar 25	2.29
Mar 25	2.06
Mar 25	2.06
Feb 25	2.23
Feb 25	2.24
Feb 25	2.61
Feb 25	2.44
Jan 25	2.74
Jan 25	2.59
Jan 25	2.43
Jan 25	2.36
Jan 25	3.01
Dec 24	2.86
Dec 24	2.76
Dec 24	3.08
Dec 24	3.63
Nov 24	3.66
Nov 24	3.5
Nov 24	3.36
Nov 24	3.9
Nov 24	3.8
Oct 24	3.7
Oct 24	3.86
Oct 24	4.06
Oct 24	4.4
Sep 24	4
Sep 24	3.8
Sep 24	3.56

No video analysis for this stock yet. Request one from our team.

News: PDSB

defenseworld.net · 9 Sep 2026

Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 1,957 call options on the stock. This represents an increase of 1,154% compared to the average daily volume of 156 call options. Analyst Upgrades and Downgrades Several research firms recently issued reports on PDSB.

globenewswire.com · 8 Sep 2026

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (“PIPE”) transaction.

globenewswire.com · 13 Aug 2026

PDS Biotech Reports Second Quarter 2026 Financial Results

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.

benzinga.com · 11 Aug 2026

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.

globenewswire.com · 11 Aug 2026

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D.